Beyond Alcohol: The Silent Epidemic of Fatty Liver and Fibrosis in India
A groundbreaking study published in Lancet Southeast Asia has uncovered a startling health crisis in India: approximately 40% of the population suffers from fatty liver disease unrelated to alcohol consumption, with at least 2.4% experiencing fibrosis, a precursor to severe liver damage. The research, based on data from over 7,000 participants across 27 cities, highlights a silent but growing threat to public health.
Key Findings from the Phenome India Cohort
The study, led by Dr. Shantanu Sengupta of the Phenome India cohort, excluded alcohol consumers to focus on non-alcoholic fatty liver disease (NAFLD). It found that 38.9% of surveyed individuals had fatty liver, with men disproportionately affected at 45.9% compared to 33% of women. The prevalence varied regionally, from a low of 27% in Thiruvananthapuram to highs of 50% in Roorkee and Bhopal. Major cities like Delhi, Bengaluru, Pune, Hyderabad, and Chennai reported rates between 37% and 42%.
Fibrosis, a condition where liver tissue stiffens due to repeated injury, was significantly more common among those with fatty liver: 6.3% versus 1.7% in the general study population. This is critical because fibrosis often progresses to cirrhosis, liver failure, and cancer. The highest fibrosis rates were observed in Jorhat (8.3%), Delhi (4.8%), and Jammu (4.3%), suggesting regional dietary, genetic, or environmental influences.
Link to Obesity, Diabetes, and Metabolic Health
The study revealed strong correlations between fatty liver and other health metrics:
- Obesity and Overweight: 93.7% of those with fatty liver were obese or overweight, compared to 71.1% overall.
- Diabetes Indicators: Individuals with fatty liver had higher HbA1c levels (6.2 vs. 5.7), indicating poorer blood sugar control over three months and a heightened risk of diabetes.
- Fibrosis in High-Risk Groups: Fibrosis prevalence was 9.1% among diabetics and 8.1% among obese individuals, underscoring the interconnectedness of metabolic disorders.
Dr. Sengupta emphasized, "These findings highlight the importance of liver disease, which often goes unnoticed compared to heart disease or cancer in chronic disease management." The cohort primarily represents middle-class urban and peri-urban populations, with data gaps in rural areas.
Urgent Need for Prevention and Screening Programs
Given the high prevalence of fatty liver and fibrosis, the study calls for enhanced prevention, diagnosis, and treatment initiatives. Fibroscan tests, the current standard for detecting fibrosis, are not widely accessible. To address this, researchers are developing a simpler screening method using blood biomarkers and basic demographic data like age, height, and weight.
Dr. Sengupta explained, "This approach won't provide a definitive diagnosis but will efficiently identify at-risk individuals for further testing, making early intervention more feasible." Such measures are vital to curb the progression of liver disease and reduce its burden on India's healthcare system.
In summary, this study serves as a wake-up call, revealing that non-alcoholic fatty liver and fibrosis are widespread in India, closely tied to obesity and diabetes. Proactive screening and public health strategies are essential to mitigate this silent epidemic.
